Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned trial for thiouredobutyronitrile (Kevetrin) in patients with retinoblastoma.

Trial Profile

Planned trial for thiouredobutyronitrile (Kevetrin) in patients with retinoblastoma.

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thioureidobutyronitrile (Primary)
  • Indications Retinoblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 According to a Cellceutix media release, the U.S. FDA has granted Rare Pediatric Disease Designation to thioureidobutyronitrile [Kevetrin] for the treatment of retinoblastoma.
    • 23 Nov 2015 According to a Cellceutix Corporation media release, the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kevetrin for the treatment of retinoblastoma.
    • 19 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top